tbuckley/cabot-search huggingface dataset:
Ebola: what lessons for the International Health Regulations?
Authors: None The Lancet
Journal: The Lancet (2014)

With more than 3000 deaths since the first case was confirmed in March, 2014, and after months of slow, fragmented responses, the international community has recognised Ebola as a public health emergency of international concern and a clear threat to global health security. It is the subject of a high-level UN Security Council resolution, and has triggered the creation of a UN Mission for Ebola Emergency Response. Despite these efforts, Ebola is staying ahead of efforts to contain it. In such a situation, although it is understandable to focus on urgent actions, it would be a mistake not to reflect on how we arrived at this situation and what we need to do to prevent it from happening again.
Targeted Drugs Fall Short in Squamous Lung Cancer
Journal: Cancer Discovery (2020)

Abstract A massive 5 year–plus effort to find molecularly targeted therapies for patients with recurrent, advanced-stage squamous cell carcinoma of the lungs has demonstrated the feasibility of rapidly screening tumors for rare genomic alterations and assigning drug treatments accordingly. Yet, the Lung Cancer Master Protocol study has yet to identify a broadly effective targeted agent for patients with biomarker-defined subtypes of the disease.
Staged versus non staged approach for multivessel percutaneous coronary interventions Andrea S. Abizaid, Roxana Mehran, Alexandre Abizaid, George Dangas, Luis Gruberg, Augusto D. Pichard, Ron Waksman, Lowell F. Satler, Kenneth M. Kent, Alexandra J. Lansky, Gregg W. Stone, Martin B. Leon. Cardiovascular Research Foundation, New York, NY, Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
Overview on the Application of Transcription Profiling using Selected Nephrotoxicants for Toxicology Assessment
Authors: Jeffrey A. Kramer, Syril D. Pettit, Rupesh. P. Amin, Timothy A. Bertram, Bruce Car, Michael Cunningham, Sandra W. Curtiss, John W. Davis, Clive Kind, Michael Lawton, Jorge M. Naciff, Victor Oreffo, Richard J. Roman, Frank D. Sistare, James Stevens, Karol Thompson, Alison E. Vickers, Stacey Wild, Cynthia A. Afshari
Journal: Environmental Health Perspectives (2004)

Microarrays allow for the simultaneous measurement of changes in the levels of thousands of messenger RNAs within a single experiment.As such, the potential for the application of transcription profiling to preclinical safety assessment and mechanism-based risk assessment is profound.However, several practical and technical challenges remain.Among these are nomenclature issues, platform-specific data formats, and the lack of uniform analysis methods and tools.Experiments were designed to address biological, technical, and methodological variability, to evaluate different approaches to data analysis, and to understand the application of the technology to other profiling methodologies and to mechanism-based risk assessment.These goals were addressed using experimental information derived from analysis of the biological response to three mechanistically distinct nephrotoxins: cisplatin, gentamicin, and puromycin aminonucleoside.In spite of the technical challenges, the transcription profiling data yielded mechanistically and topographically valuable information.The analyses detailed in the articles from the Nephrotoxicity Working Group of the International Life Sciences Institute Health and Environmental Sciences Institute suggest at least equal sensitivity of microarray technology compared to traditional end points.Additionally, microarray analysis of these prototypical nephrotoxicants provided an opportunity for the development of candidate bridging biomarkers of nephrotoxicity.The potential future extension of these applications for risk assessment is also discussed.
Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single-arm, multicenter, phase II clinical trial—Update results from ALTER-C001.
Authors: Jin Yan, Yunwei Han, Li Zhang, Yongdong Jin, Hao Sun
Journal: Journal of Clinical Oncology (2022)

104 Background: The combination of anti-VEGF or anti-EGFR targeted drugs with chemotherapy is the standard first-line therapy for metastatic colorectal cancer (mCRC), and the followed maintenance treatment is an optional approach to balance the efficacy and toxicity. However, studies regarding the maintenance strategies based on antiangiogenic TKIs are limited currently. Anlotinib, a novel oral multi-target TKI which can inhibit both tumor angiogenesis and tumor cell proliferation simultaneously, substantially prolonged the PFS with manageable toxicity for refractory mCRC in the phase III ALTER0703 clinical trial (NCT02332499). We present updated data from the study of anlotinib plus XELOX as first-line treatment followed by anlotinib monotherapy for mCRC. Methods: In this open label, single-arm, multicenter phase II clinical trial, 29 mCRC patients without prior systemic treated, aged 18-75 and an ECOG performance status of 0 or 1 were planned to recruit. Eligible patients received capecitabine (1000 mg/m 2 , po, d1-14, q3w) and oxaliplatin (130 mg/m 2 , iv, d1, q3w) plus anlotinib (10mg, po, d1̃14, q3w) treatment for 6 cycles. After 6 cycles of inducing therapy, patients would receive anlotinib (12mg, po, d1̃14, q3w) as maintenance therapy until disease progression or intolerable adverse events (AEs). The primary endpoint was PFS; Secondary endpoints included ORR, DCR, DOR and safety. Results: At updated analysis (cutoff: Sep 10, 2021), a total of 27 patients were enrolled, of which 19 patients were available for efficacy assessment. In best overall response assessment, there were 63.2% PR (12/19), 26.3% SD (5/19) and 10.5% PD (2/19). The ORR was 63.2% (95% CI, 38.4-83.7%) and DCR was 89.5% (95% CI, 66.9-98.7%). One patient experienced the longest duration of treatment which was 17.5 months. The median PFS was not reached. The most common treatment related adverse events (TRAEs) of any grade (≥25%) were leukopenia, nausea/vomiting, hypertension, neutropenia, hypohemoglobinemia, hypertriglyceridemia. Grade 3/4 TRAEs (≥10%) were neutropenia (14.8%), hypertension (14.8%) and hypertriglyceridemia (11.1%). One grade 5 TRAE was pancytopenia that occurred at 2.7 months. Conclusions: The update results suggested that anlotinib combined with XELOX as first line regimen followed by anlotinib monotherapy showed promising anti-tumor activity and manageable safety for patients with mCRC. And the conclusions needed to be confirmed in randomized studies. Clinical trial information: ChiCTR1900028417.
Error in Figure Caption
Authors: Kevin Alexander, Sharmila Dorbala
Journal: JAMA Cardiology (2021)

tality rate seen in Black individuals in the study by Sidney et al. 1 Despite the high prevalence of ATTR cardiomyopathy among elderly individuals and high age-adjusted mortality from amyloidosis in Black individuals, cardiac amyloidosis remains significantly underdiagnosed. 4 In 2019, the US Food and Drug Administration approved tafamidis, the first diseasemodifying drug for ATTR cardiomyopathy, which significantly reduces mortality and cardiovascular hospitalizations. 5Therefore, it is imperative that we improve the diagnosis of this treatable disease.
AMA Specialty Journal Abstracts
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mirs-138 and -424 Control Palmitoylation-Dependent CD95-Mediated Cell Death By Targeting Acyl Protein Thioesterases 1 and 2 in Chronic Lymphocytic Leukemia
Authors: Valeska Berg, Marion Rusch, Nachiket Vartak, Christian Juengst, Astrid Schauss, Herbert Waldmann, Christian Hedberg, Christian P. Pallasch, Philippe Bastiaens, Michael Hallek, Clemens-Martin Wendtner, Lukas P. Frenzel
Journal: Blood (2014)
Frequency of immunostimulatory herbal supplement use among patients with autoimmune skin disease
Authors: Adarsh Ravishankar, Christina E. Bax, Madison Grinnell, Daisy Yan, Josef S. Concha, Lisa Pappas-Taffer, Bridget E. Shields, Mohammed Dany, Ashley K. Clark, Rui Feng, Joyce Okawa, Victoria P. Werth
Journal: Journal of the American Academy of Dermatology (2022)
Infectious Diarrhea
Authors: M J Rubinoff, M Field
Journal: Annual Review of Medicine (1991)

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 ...Read More
Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic adenocarcinoma (mPC): PCRT16-001.
Authors: David Bing Zhen, Martin Whittle, Paul S. Ritch, Howard S. Hochster, Andrew L. Coveler, Ben George, Andrew Eugene Hendifar, Tomislav Dragovich, Steven Green, Barbara Dion, Amy C. Stoll-D'Astice, Arthur Lee, Shelley M. Thorsen, Adam Rosenthal, Sunil R. Hingorani, E. Gabriela Chiorean
Journal: Journal of Clinical Oncology (2022)

576 Background: Stromal HA poses a physical barrier and protects tumor cells from immune surveillance. PEGPH20 is a pegylated, human recombinant PH20 hyaluronidase that remodels tumor stroma. Preclinical studies of PEGPH20 showed improved infiltration of cytotoxic T-lymphocytes and delivery of chemotherapy and PD1/PD-L1 antibodies. This study aimed to evaluate the efficacy, safety, and translational biomarkers of PEGPH20 plus pembrolizumab in pts with HA-high refractory mPC. Methods: mPC pts with HA-high expression, ECOG PS 0-1, ≤ 2 prior therapies for metastatic disease, life expectancy ≥ 12 weeks were treated with PEGPH20 3 µg/kg iv on D1, D8, D15 and pembrolizumab 200 mg iv on D1 in 21-day cycles. Primary endpoint was progression-free survival (PFS). Secondary endpoints were safety, overall survival (OS), and objective response rate (ORR). Blood and tumor biopsies were collected at baseline and on-study. Translational endpoints included flow cytometry and IHC for immune subsets, T-cell receptor sequencing, immune transcriptome, circulating cytokines, and plasma and tumor HA levels. Assuming a one-sided α-level of 0.05 and power of 80%, 31 evaluable pts were needed to detect an improvement of median PFS from 3 to 6 months. Results: Between May 2019 to Nov 2019, 38 pts were screened for HA expression, and 8 pts were enrolled, with median age 68 years (range 60-73), 7 males, and median 2 prior therapies (range 1-4). The accrual was stopped early by Halozyme Pharmaceuticals due to lack of benefit from PEGPH20 added to chemotherapy in the HALO-301 study. Treatment exposure median was 2 cycles (range 1-6). Reasons for study discontinuation were disease progression (n = 4), termination by sponsor (n = 3), patient withdrawal to enroll in hospice (n = 1). Treatment related toxicities were musculoskeletal (n = 6, grade 1/2), edema (n = 2, grade 1), fatigue (n = 1, grade 3), dyspnea (n = 1, grade 2), hypothyroidism (n = 1, grade 2). Median OS was 7.2 months (95% CI 1.2-11.8), and median PFS was 1.5 months (95% CI 0.9-4.4). Best response was stable disease (n = 2, 25%) lasting 2.2 and 9 months, respectively, and no responses were noted. Patients with available molecular sequencing data had MSS tumors. Translational biomarkers will be presented. Conclusions: Pembrolizumab and PEGPH20 did not increase PFS compared to historical data among heavily pretreated mPC pts, but the median OS of 7.2 months is encouraging. Translational analyses will provide insights into immune modulatory effects from PEGPH20 that could inform future studies with stroma targeted therapies and immune checkpoint blockade in mPC. Clinical trial information: NCT03634332.
Selected New Books
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human Biochemistry
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICAL PROGRESS.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 245: Heart Failure With Preserved Ejection Fraction- a New Animal Model and a Novel Mechanistic Perspective
Authors: Claire L Curl, Vennetia R Danes, James R Bell, Antonia J Raaijmakers, Wendy T Ip, Chanchal Chandramouli, Tristan W Harding, Kimberley M Mellor, Jonathan Kalman, Stephen B Harrap, Lea M Delbridge
Journal: Circulation Research (2017)

Diagnosis of heart failure with preserved ejection fraction (HFpEF) is becoming the prevalent form of disease type. Established treatments for heart failure with reduced ejection fraction (HFrEF) have proven minimally effective for HFpEF. This may reflect differences in underlying cardiomyocyte pathophysiology. In HFrEF cardiomyocyte phenotype is characterized by impaired contractile response and diminished systolic Ca 2+ levels. Studies of intact HFpEF-derived cardiomyocytes are lacking. Progress in understanding the etiology of HFpEF has been impeded by limited availability of appropriate pre-clinical models. Our goal was to validate and characterize a new rodent model of HFpEF, the ‘Hypertrophic Heart Rat’ (HHR), undertaking longitudinal investigations to delineate the associated cardiac and cardiomyocyte pathophysiology. The selectively inbred HHR strain exhibits adult cardiac enlargement (without hypertension) and premature mortality (40% at age 50 weeks) compared to the control ‘Normal Heart Rat’ (NHR). Echo analyses established that cardiac hypertrophy was characterized in vivo by maintained systolic parameters (i.e. ejection fraction at 85-90% control) with marked diastolic dysfunction (i.e. increased E/E’). Diastolic dysfunction was detectable in young adult HHR, as an early disease marker. Histological examination identified regions of focal reparative fibrosis in HHR hearts, most prominent in the transverse midwall area of the left ventricle adjacent to the interventricular septum. Evaluation of cardiomyocyte function using left ventricular myocytes isolated from hearts of 30 week (prefailing ) HHR revealed a hypercontractile phenotype with high Ca 2+ operational levels and arrhythmogenic vulnerability. HHR cardiomyocytes exhibited dramatically increased L-type Ca 2+ channel current density (almost 2-fold), and molecular analyses identified hyperphosphorylation of key sarcoplasmic reticulum Ca 2+ regulatory proteins, without change in total phospho-titin. These findings strongly support the contention that HFpEF and HFrEF can have different underlying cardiomyocyte phenotypes. New directions for HFpEF therapies are indicated, and the HHR provides a new model for preclinical HFpEF investigations.
WASHINGTON NEWS
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A PALATE-TONSIL RETRACTOR
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
对化疗所致脱发的更深入了解
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Piccini et al. Br J Dermatol 2022; 186:129–141. 脱发是化疗更严重也最令人恐惧的副作用之一, 可显著影响接受此类治疗的患者的生活质量。有时, 这甚至会导致患者 (尤其是女性患者) 拒绝接受治疗。幸运的是, 在几乎所有患者中, 头发会在停止治疗后 3 个月内恢复生长。然而, 在一些患者中, 脱发可能是永久性的, 这会为患者带来巨大的痛苦。不幸的是, 目前尚无有效的治疗方法来预防或恢复这些患者的毛发生长。 在这项国际研究中, 我们使用从健康者的头皮中采集的头发样本, 在实验室中诱导一种模拟癌症患者化疗效果的症状。我们发现, 化疗可导致毛囊中的细胞受损, 而这些细胞负责补充掌管毛发生长的细胞, 属于干细胞中的一种。化疗不仅会引发最终导致这些干细胞死亡的事件, 而且还会刺激这些细胞转化为瘢痕组织, 这是一种不可逆的过程, 会阻止新毛发生长。 随着我们对导致头发损伤的机制有了更深入的了解, 我们尝试在实验室中使用一种名为 NAGED 的化合物 (N-乙酰基-GED-0507-34-Levo) , 以保护干细胞免受耗竭和损伤。虽然目前还无法在临床环境中使用这一新信息, 但本研究为开发一种可能应用于头皮的潜在治疗方法提供了希望, 并且这种治疗方法或许能够在接受化疗的癌症患者中预防永久性脱发。 Linked Article: Piccini et al. Br J Dermatol 2022; 186:129–141.
Exploration of Sleep Parameters, Daytime Hyperactivity/Inattention, and Attention-Deficit/Hyperactivity Disorder Polygenic Risk Scores of Children in a Birth Cohort in Japan
Authors: Nagahide Takahashi, Akemi Okumura, Tomoko Nishimura, Taeko Harada, Toshiki Iwabuchi, Md Shafiur Rahman, Kenji J. Tsuchiya
Journal: JAMA Network Open (2022)

This cohort study examines whether sleep problems and polygenic risk scores for attention-deficit/hyperactivity disorder are associated with hyperactivity/inattention symptoms in children aged 8 to 9 years from the general population in Japan.